Abstract:Abstract Abstract 1520 Purpose: Older patients are likely to have more comorbidities or a poor clinical condition. Deciding which older acute myeloid leukemia (AML) patients would benefit from intensive chemotherapy, especially in most patients ≥70 years of age is not clear. We conducted a phase 2 study exploring the feasibility, safety, and biologic activity in vitro of combination of decitabine, low-dose cytarabine and aclarubicin with granulocyte colony-stimulating factor (G-CSF) priming for the induction chemotherapy of older patients with myelodysplastic syndromes (MDS) and AML. Patients and Methods: Fifty consecutive patients (median age 65 years, range 60 to 80 years, 15 of age ≥70 years) with MDS (n= 15) or AML (n= 35) were enrolled. Cytogenetic analysis was performed in all the patients, showing 3 patients have inadequate mitotic cells. According to WHO, only 15 patients had MDS, and 35 AML (22 de novo, 11 AML/MDS, 2 AML/MDS therapy-related). Ten patients (71.4%) had low-risk cytogenetics according to IPSS. Two patients (14.3%) had intermediate-risk and 2 (14.3%) had high-risk cytogenetics. According to the Grimwade definition for AML, none of patients had favorable cytogenetics, 31(91.2%) had intermediate-risk karyotypes and 3 patients (8.8%) had adverse cytogenetics. All patients were treated with low-dose decitabine 15 mg/m2 intravenously for 5 consecutive days (d1–5) in combination with cytarabine 10 mg/m2 q12h for 7 days (d3–9) and aclarubicin 10mg every day for 4 days (d3–6) and G-CSF 300 μg every day (d 0–9) priming (D-CAG). G-CSF was withdrawn when the white blood cell count (WBC) >20×109/L. Hydroxyurea was given until WBC was <10×109/L and withdrawn before decitabine was given. Response was assessed by weekly complete blood count and bone marrow biopsy was taken at the time of recovery of peripheral hemogram or 3–4 weeks later after each course. All of patients underwent baseline and efficacy evaluations. In vitro study, we first evaluated the cytotoxic effect of decitabine, cytarabine and aclarubicin as single agents in HL60 cell lines. And next we investigated whether the cytotoxic effect on combination with these three agents. Results: The combination of DAC, cytarabine and aclarubicin showed synergistic induction of cell death in HL60 cell lines. A degree of combination effect was observed at point that decitabine was administered before cytarabine and aclarubicin, which was maximal at 48h before cytarabine and aclarubicin. In older patients, of the 48 patients evaluable for response, the overall response rate (ORR) was 42/48 (87.5%), complete remission (CR) 77.1% (n=37) after one cycle. Two patients were not evaluable for response because of early death. Five patients with partial remission (PR) or non-response received second cycle of induction therapy and four attained CR. ORR in 30 patients with normal karyotype was 90%, CR 73.3% after first cycle, and 90% after second cycles. Eleven of the 13 patients with aberrant chromosome achieved a CR. Patients with cytogenetic alterations, excluding −5/-7, had an CR of 88.9%. After first cycle, in the 11 evaluable patients with aberrant chromosome, 9 patients achieved CR, including −5/-7, were as always accompanied by CR as assessed by conventional cytogenetics. All patients completed the treatment and there was no induction mortality. The 4-week death rate was 5.7% (2 patients). Grade 4 neutropenia and thrombocytopenia was universal. Median duration of granulocyte recovery (0.5×109/L) was 12 days (0–40), and that of platelet recovery (x109/L) was 11 days (0–40).10 days and there were no thrombotic complications including one patient with atrial fibrillation. The most common toxicities were myelosuppression, febrile neutropenia. With a median follow-up of 34.2 weeks (range, 8–116 weeks), median overall survival (OS) for the whole group was 34.2 weeks (range, 8–116 weeks), and event free survival (EFS) was 30 weeks (range, 8.6 to 107 weeks). EFS was poorer in patients with −5/-7 cytogenetic. There was no different survival in the patients aged 60 to 69 years versus the group aged ≥70 years (p=0.283). OS for responders is significantly longer than that of nonresponders (p=0.000). Conclusion: The study suggests D-CAG improved outcomes in older patients with untreated/relapsed AML, MDS and was well tolerated. The response rate was not adversely influenced by poor-risk cytogenetics or MDS and was associated with low induction mortality and high rates of CR Disclosures: No relevant conflicts of interest to declare.

Fast proliferating and slowly migrating non‐small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment

Epigenetic Priming with Decitabine Followed by Low-Dose Idarubicin Plus Cytarabine in AML Evolving from MDS or Higher Risk MDS: A Multicentre Phase 2 Single-Arm Trial

Sequential Combination of Decitabine and Idarubicin Synergistically Enhances Anti-Leukemia Effect Followed by Demethylating Wnt Pathway Inhibitor Promoters and Downregulating Wnt Pathway Nuclear Target

Synergistic Effect of Sequential Combination of Decitabine and Idarubicin in Mouse Model of Human Acute Myeloid Leukemia

AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors

Chemotherapy-induced CDA expression renders resistant non-small cell lung cancer cells sensitive to 5′-deoxy-5-fluorocytidine (5′-DFCR)

Tet2 Downregulation Leads To Aml Cells Sensitive To Decitabine

Retinoic Acid Receptor-β Gene Reexpression and Biological Activity in SHI-1 Cells after Combined Treatment with 5-Aza-2′-Deoxycytidine and All-Trans Retinoic Acid

Tetrahydrouridine/decitabine/5-azacytidine for Non-Cytotoxic Epigenetic-Immunotherapy of NSCLC in Vivo.

All -trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RARα-Nrf2 complex

In Vivo Validation of Novel P53-Independent Therapeutic Modalities for Small Cell Lung Cancer (SCLC).

Evaluation of Combined Chemotherapy and Genomic-Driven Targeted Therapy in Patient-Derived Xenografts Identifies New Therapeutic Approaches in Squamous Non-Small-Cell Lung Cancer Patients

Decitabine, Low-Dose Cytarabine and Aclarubicin Combination with Granulocyte Colony-Stimulating Factor Priming for the Induction Chemotherapy of Older Patients with Myelodysplastic Syndromes and Acute Myeloid Leukemia

The Safety, Efficacy, And Treatment Outcomes Of A Combination Of Low-Dose Decitabine Treatment In Patients With Recurrent Ovarian Cancer

Tetrahydrouridine-decitabine for Non-Cytotoxic Epigenetic Therapy of NSCLC to Enhance Immunotherapeutic Effect of Anti-Pd1 in Vivo.

Synergistic anti-tumor effects of lenalidomide and gefitinib by upregulating ADRB2 and inactivating the mTOR/PI3K/AKT signaling pathway in lung adenocarcinoma

Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy

Abstract 1844: Proteomic characterization of decitabine resistance in acute myeloid leukemia reveals signaling pathway crosstalk dampens the effectiveness of combination therapy

Falnidamol and cisplatin combinational treatment inhibits non-small cell lung cancer (NSCLC) by targeting DUSP26-mediated signal pathways

Abstract 3400: Single-cell proteogenomics analysis of AML samples treated with decitabine and venetoclax reveals divergent treatment escape mechanisms